Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 11:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 76 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Coronary Artery Disease Risk High Clear all
Not listed Phase 3 Interventional

Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

NCT04806893
View directory record Official record
Conditions
Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Stroke, Hypercholesterolemia
Interventions
lerodalcibep, Placebo
Drug · Other
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 1, 2026, 11:59 PM EDT
Terminated Phase 3 Interventional Results available

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

NCT01975389
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
bococizumab (PF-04950615), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
10,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
518
States / cities
Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 328 more
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 1, 2026, 11:59 PM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 1, 2026, 11:59 PM EDT
Recruiting Not applicable Interventional

Breaking Fasts Ahead of Cardiac Caths

NCT06996639
View directory record Official record
Conditions
Stable Angina (SA), Unstable Angina (UA), NSTEMI - Non-ST Segment Elevation MI
Interventions
Non-Fasting, Fasting
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 1, 2026, 11:59 PM EDT
Recruiting Phase 4 Interventional

Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

NCT07025148
View directory record Official record
Conditions
Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 1, 2026, 11:59 PM EDT
Completed Not applicable Interventional Results available

XIENCE 28 USA Study

NCT03815175
View directory record Official record
Conditions
Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases, Thrombocytopenia, Coagulation Disorder, Anemia, Renal Insufficiency, Coronary Artery Disease
Interventions
XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
54
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 1, 2026, 11:59 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)

NCT00414609
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Aliskiren, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Novartis US, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 13, 2012 · Synced Oct 1, 2026, 11:59 PM EDT
Recruiting No phase listed Observational

IVUS CHIP UPP Registry

NCT06625801
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Disease Risk High, Complex Coronary Artery Disease
Interventions
IVUS
Device
Lead sponsor
ECRI bv
Industry
Eligibility
18 Years and older
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Loma Linda, California • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 1, 2026, 11:59 PM EDT
Terminated Phase 2 Interventional Results available

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

NCT03606642
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Stent Placement
Interventions
Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
Drug · Device
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
75 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 1, 2026, 11:59 PM EDT
Completed Phase 3 Interventional Results available

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

NCT01327846
View directory record Official record
Conditions
Atherosclerosis
Interventions
Canakinumab, Placebo, Standard of care
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
10,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
315
States / cities
Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 248 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 1, 2026, 11:59 PM EDT
Completed No phase listed Observational

Restore EF Observational Study

NCT04648306
View directory record Official record
Conditions
Coronary Artery Disease, Unstable Angina, Angina, Stable, NSTEMI - Non-ST Segment Elevation MI
Interventions
Prophylactic Impella support for a non-emergent PCI
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 1, 2026, 11:59 PM EDT
Completed Phase 4 Interventional

18F-fluoride (18F-NaF) PET for Identifying Coronary Atherosclerotic Plaques

NCT02607748
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerotic Plaque
Interventions
18F-NaF PET and coronary CTA imaging
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 1, 2026, 11:59 PM EDT
Active, not recruiting Not applicable Interventional

Invest-CTO PCI Trial

NCT04774913
View directory record Official record
Conditions
Chronic Total Occlusion of Coronary Artery, Angina Pectoris, Quality of Life, PROM
Interventions
Chronic total occlusion(CTO) percutaneous coronary intervention (PCI)
Procedure
Lead sponsor
Haukeland University Hospital
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 1, 2026, 11:59 PM EDT
Completed Not applicable Interventional

VITALYST Early Feasibility Study in High-Risk PCI Patients (VITALYST EFS)

NCT06132568
View directory record Official record
Conditions
High-risk Percutaneous Coronary Intervention, Heart Disease, Coronary
Interventions
VITALYST System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 1, 2026, 11:59 PM EDT
Recruiting Phase 4 Interventional

The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk

NCT05152888
View directory record Official record
Conditions
Stable Coronary Disease
Interventions
Evolocumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 1, 2026, 11:59 PM EDT
Completed No phase listed Observational

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

NCT00377949
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma, Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 75 Years
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
25
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 1, 2026, 11:59 PM EDT
Recruiting No phase listed Observational

A Precision Medicine Approach to Identify Patients Undergoing Elective PCI at Risk of Peri-PCI Myocardial Infarction

NCT05332262
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Assessment of platelet reactivity, Troponin measurement
Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 1, 2026, 11:59 PM EDT
Completed Phase 2 Interventional

Heart Disease on the Mend

NCT00127751
View directory record Official record
Conditions
Coronary Heart Disease, Stroke, Hyperlipidemia, Hypertension
Interventions
Enhance health lifestyle changes and medication compliance
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
35 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2005 · Synced Oct 1, 2026, 11:59 PM EDT
Recruiting Not applicable Interventional

Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

NCT07296744
View directory record Official record
Conditions
Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support
Interventions
The Supira System, Impella
Device
Lead sponsor
Supira Medical
Industry
Eligibility
18 Years to 90 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
24
States / cities
Loma Linda, California • Sacramento, California • Thousand Oaks, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 1, 2026, 11:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Genes That May Increase the Risk for Heart Disease in African Americans

NCT00344136
View directory record Official record
Conditions
Heart Diseases
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 95 Years
Enrollment
5,302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 1, 2026, 11:59 PM EDT
Completed Phase 2 Interventional

MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)

NCT00157716
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury, Myocardial Revascularization
Interventions
(MC-1) Pyridoxal-5'-phosphate
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2006 · Synced Oct 1, 2026, 11:59 PM EDT
Completed No phase listed Observational

Pressure-Volume Loop During High-Risk PCI

NCT04681313
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
High-risk percutaneous coronary intervention
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 1, 2026, 11:59 PM EDT
Completed Not applicable Interventional

Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin

NCT01931852
View directory record Official record
Conditions
Acute Coronary Syndrome, Chest Pain
Interventions
Cardiac MRI, ACC/AHA Guideline adherent care
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Royal Oak, Michigan • Jackson, Mississippi • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 1, 2026, 11:59 PM EDT
Completed Not applicable Interventional Results available

A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear)

NCT03647475
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT
Combination Product
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
East Syracuse, New York • New York, New York • Anderson, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 1, 2026, 11:59 PM EDT